Orally administered plastid expressed cholera toxin B subunit-exendin 4 as treatment for type 2 diabetes
AssigneeThe Trustees of the University of Pennsylvania
InventorHenry Daniell
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for treating Type II diabetes. The compositions comprise plant expressed Exendin 4. Particularly exemplified are plant derived compositions that include a CTB-EX4 conjugate that is bioencapsulated in chloroplasts.
Claims17
A plant plastid comprising a plastid genome transformed with a heterologous expression cassette consisting of, as operably linked components in the 5′ to the 3′ direction of translation, a flanking sequence having homology to a trnl region in the plastid genome, a Prrn promoter operative in said plastid, an aadA selectable marker sequence or an antibiotic free selectable marker sequence, a psbA 5′ untranslated region sequence, a cholera toxin B subunit(CTB)-Exendin fusion gene sequence, a psbA 3′ untranslated region sequence, and a flanking sequence having homology to a trnA region in the plastid genome, said expression cassette being integrated into said plastid genome such that said CTB-Exendin is expressed in and present in said plastid, wherein the CTB-Exendin 4 fusion protein has a hinge region, and a furin cleavage site between the CTB and the Exendin 4, and wherein the hinge-furin cleavage site-exendin portion consists of SEQ ID NO:
- 7, said plastid being suitable for oral administration of said CTB-Exendin 4 to a subject in need thereof.
Dependencies are inferred from the claim text.